Profile data is unavailable for this security.
About the company
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
- Revenue in USD (TTM)14.09bn
- Net income in USD4.50bn
- Incorporated1988
- Employees15.11k
- LocationRegeneron Pharmaceuticals Inc777 Old Saw Mill River RoadTARRYTOWN 10591United StatesUSA
- Phone+1 (781) 370-5000
- Websitehttps://www.regeneron.com/
Mergers & acquisitions
| Acquired company | REGN:NSQ since announced | Transaction value |
|---|---|---|
| 23andMe Holding Co | -7.90% | 256.00m |
| Oxular Ltd | -22.09% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICON PLC | 8.19bn | 758.19m | 11.93bn | 41.25k | 16.33 | 1.26 | 9.99 | 1.46 | 9.19 | 9.19 | 99.32 | 119.56 | 0.4852 | -- | 3.01 | 195,528.00 | 4.49 | 3.70 | 5.39 | 4.46 | 29.08 | 29.00 | 9.25 | 7.41 | -- | 5.82 | 0.2647 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Exelixis Inc | 2.30bn | 643.57m | 12.59bn | 1.15k | 20.94 | 5.96 | 18.69 | 5.47 | 2.20 | 2.20 | 7.88 | 7.75 | 0.8151 | 3.23 | 8.80 | 2,004,291.00 | 22.82 | 9.51 | 26.44 | 10.77 | 96.78 | 96.32 | 27.99 | 15.61 | 3.44 | -- | 0.00 | 0.00 | 18.49 | 17.51 | 150.89 | 10.18 | 17.25 | -- |
| Summit Therapeutics Inc | 0.00 | -240.76m | 18.23bn | 159.00 | -- | 52.88 | -- | -- | -0.3309 | -0.3309 | 0.00 | 0.4643 | 0.00 | -- | -- | 0.00 | -85.89 | -78.31 | -95.86 | -86.84 | -- | -- | -- | -31,307.77 | -- | -- | 0.00 | -- | -- | -- | 64.01 | -- | -16.43 | -- |
| Insmed Inc | 381.03m | -1.01bn | 18.55bn | 1.27k | -- | 179.41 | -- | 48.69 | -5.95 | -5.95 | 2.21 | 0.5451 | 0.2573 | 0.9753 | 8.98 | 299,787.60 | -68.42 | -44.83 | -88.04 | -51.79 | 76.49 | 77.08 | -265.93 | -226.78 | 5.44 | -31.80 | 0.9194 | -- | 19.17 | 21.66 | -21.91 | -- | -12.30 | -- |
| Iqvia Holdings Inc | 15.50bn | 1.33bn | 28.41bn | 89.00k | 22.38 | 4.78 | 11.58 | 1.83 | 7.34 | 7.34 | 85.31 | 34.33 | 0.5751 | -- | 4.63 | 176,102.30 | 4.97 | 4.03 | 6.65 | 5.17 | 34.72 | 34.47 | 8.64 | 7.28 | -- | 3.65 | 0.7054 | 0.00 | 2.81 | 6.80 | 1.10 | 48.36 | 0.678 | -- |
| Regeneron Pharmaceuticals Inc | 14.09bn | 4.50bn | 59.10bn | 15.11k | 13.93 | 2.02 | 11.83 | 4.20 | 39.30 | 39.30 | 123.45 | 271.60 | 0.3917 | 0.6347 | 2.61 | 932,457.30 | 12.51 | 18.52 | 13.89 | 21.13 | 86.69 | 87.22 | 31.94 | 37.92 | 4.03 | -- | 0.0843 | -- | 8.27 | 12.55 | 11.61 | 15.84 | 15.46 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 8.91m | 8.29% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2025 | 7.00m | 6.52% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 5.74m | 5.34% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 4.79m | 4.46% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2025 | 3.99m | 3.71% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2025 | 3.99m | 3.71% |
| Geode Capital Management LLCas of 31 Mar 2025 | 2.47m | 2.30% |
| Dodge & Coxas of 31 Mar 2025 | 2.32m | 2.16% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Mar 2025 | 2.02m | 1.88% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2025 | 1.94m | 1.80% |
